Furthermore, another recent study suggests that specific inflammatory biomarkers that are known to be produced by activated microglia and which correlate with TSPO VT, might serve for selection of MDD patients most apt to benefit from augmentative anti-inflammatory therapy (Attwells et al., 2020). This evidence concerns the gene TSPO and major depressive disorder.